Background {#Sec1}
==========

*Pseudomonas aeruginosa*, an opportunistic pathogen, is an important cause of infection in patients with impaired immune systems \[[@CR1]\]. *P. aeruginosa* is a prime example of a species that has continually evolved such that many strains are extensively drug resistant---i.e., resistant to all standard anti-pseudomonal antibiotics (carbapenems and aminoglycosides) and sensitive only to colistin \[[@CR2]\]. Nowadays, intensive clinical use of carbapenems has caused the presence of carbapenem resistant *P. aeruginosa* populations \[[@CR3]\] and an increase in carbapenem resistance by acquisition of different mechanisms, such as hyperproduction of chromosomal AmpC beta-lactamase, overexpression of efflux systems, alteration or lack of outer membrane proteins (such as porin OprD), and production of carbapenemases \[[@CR4]\]. The advent of mobile MBL genes heralded a new chapter in resistance; class 1 integrons, the mobile genetic structures that carry MBL genes, also carry genes encoding determinants of resistance to aminoglycosides and other antibiotics, and thus confer extensive drug resistance \[[@CR5]\]. MBL gene *bla*~VIM-2~ was first reported in *P. aeruginosa* in France in 2000, but the earliest recorded case was in Portugal in 1995 \[[@CR6]\]. VIM-2 has emerged as a dominant MBL variant worldwide. MultiLocus sequence typing (MLST) has identified international clonal complexes (CCs) responsible for the dissemination of MBL-producing *P.aeruginosa*, particularly in European countries \[[@CR7]\], in Japan \[[@CR8]\], Singapore, and Brazil.

The aim of this study was to examine the genetic relatedness of MBL producing *P. aeruginosa* strains isolated from two hospitals in Cairo, Egypt.

Methods {#Sec2}
=======

Bacterial isolates {#Sec3}
------------------

Forty eight non-duplicate carbapenem resistant *P. aeruginosa* isolates were obtained from clinical specimens submitted for bacteriological testing from hospitalized in-patients admitted to Kasr Al Aini Hospital (KAA) and National Cancer Institute (NCI), Cairo University, Egypt from January 2011 to January 2012. KAA School of Medicine and NCI are tertiary hospitals belonging to Cairo University, Egypt. The study was approved by the Ethics Committee of Cairo University and an informed consent was obtained from all patients receiving treatment and participating in the study.

Isolate identification {#Sec4}
----------------------

Initial identification and susceptibility testing was done using VITEK 2 (bioMerieux, Marcy l'E'toile, France) automated machine. Genotypic identification was carried out by PCR amplification and sequence determination of 16S rDNA previously described by Spilker *et al.* \[[@CR9]\]. The identified strains were stored in glycerol broth cultures at - 70°C.

Antimicrobial susceptibility testing {#Sec5}
------------------------------------

Susceptibility testing was done by the disc diffusion method of the Clinical and Laboratory Standards Institute, \[[@CR10]\] with discs from Oxoid (Oxoid ltd., Basin Stoke, Hants, England). MICs were determined with E-test strips (bioMerieux, Marcy L'Etoile, France). *P. aeruginosa* ATCC 27853 was used as a control throughout.

Phenotypic detection of MBLs {#Sec6}
----------------------------

E-test MBL strips were in accordance with the manufacturer's instructions to seek MBL production. A no less than eight-fold reduction in imipenem MIC in the presence of EDTA, or a phantom zone, was taken as a positive result.

Detection of MBL-encoding genes and integrase genes {#Sec7}
---------------------------------------------------

*bla*~*VIM-2*~*, bla*~*IMP-1*~*, bla*~*SIM*~*, bla*~*GIM*~*, bla*~*SPM*~*, bla*~*NDM-2*~ and *intI1* were amplified for *P.aeruginosa* isolates using primers listed in Table [1](#Tab1){ref-type="table"} according to the previous protocols \[[@CR11]-[@CR15]\]. Negative and positive controls were involved in all PCR experiments. Five microliters of reaction mix containing PCR product were analysed by electrophoresis in 0.8% (w/v) agarose (Fermentas, Lithuania).Table 1**List of primers used in this studyPrimersSequence 5′-3′UseExpected PCR productReferencePA-SS-F**GGGGGATCTTCGGACCTCAIdentification956 bpSpilker *et al.* \[[@CR9]\]**PA-SS-R**TCCTTAGAGTGCCCACCCG***bla*** ~**IMP-1**~TGAGCAAGTTATCTGTATTC*bla* ~IMP-1~740 bpYan *et al*. \[[@CR11]\]TTAGTTGCTTGGTTTTGATGamplification**VIM-F1**ATGTTCAAACTTTTGAGTAAGTTATT*bla* ~VIM-2~801 bpFrasson *et al*. \[[@CR12]\]**VIM-FK**ATGTTAAAAGTTATTAGTAGTTTATTGKTCamplification and sequencing**VIMR1**CTACTCGGCGACTGAGC**VIMR2**CTACTCAACGACTGAGCGA***bla*** ~***NDM***~*bla* ~*NDM*~984 bpKaase *et al.* \[[@CR13]\]  ~**PreNDM-A**~CACCTCATGTTTGAATTCGCCamplification  ~**Pre-NDM-B**~CTCTGTCACATCGAAATCGC***bla*** ~**GIM**~TCGACACACCTT GGT CTG AA*bla* ~GIM~477 bpEllington *et al.* \[[@CR12]\]AACTTCCAACTT TGCCATGCamplification***bla*** ~**SPM**~AAAATCTGGGTACGCAAA CG*bla* ~SPM~271 bpEllington *et al.* \[[@CR12]\]ACATTATCCGCTGGAACAGGamplification***bla*** ~**SIM**~TAC AAG GGATTCGGCATCG*bla* ~SIM~570 bpEllington *et al.* \[[@CR12]\]TAATGG CCTGT CCCATG TGamplification***intI1****intI1*457 bpShibata *et al*. \[[@CR15]\]  **Int-1-F**GCA TCC TCG GTT TTC TGGamplification and sequencing  **Int-1-R**GGT GTG GCG GGC TTC GTG

DNA sequencing {#Sec8}
--------------

Amplified products of *bla*~VIM-2~ were purified using a QIAquick PCR Purification Kit (Qiagen, Crawley, UK) and sequenced in both directions using the ABI Prism 3700 DNA Sequencer (Applied Biosystems, Foster City, CA). The types of β-lactamase genes were identified by comparison with the sequences in GenBank (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>).

Multi-locus sequence typing (MLST) {#Sec9}
----------------------------------

PCR and sequencing of the recognized chromosomal markers (7 housekeeping genes) *acs*A, *aro*E, *gua*A, *mut*L, *nuo*D, *pps*A, and *trp*E were done \[[@CR16]\]. The nucleotide sequences of these genes were compared with the sequences submitted to the MLST database to determine the allelic numbers and sequence types.

The collection of MLST data on *P. aeruginosa* is available on <http://pubmlst.org/paeruginosa/>. MLST was performed for twenty isolates, representatives of the *bla*~VIM-2~ gene identified. All these isolates were imipenem resistant, MBL producing and VIM-2 positive. An isolate from each hospital was selected randomly for comparison.

Results {#Sec10}
=======

Of the 48 carbapenem resistant *P.aeruginosa* isolates, 33 (68.7%) were confirmed to be MBL producers. Of the 48 *P.aeruginosa* isolates, 21 isolates were from wound, 12 were from urine, 9 were from sputum,4 were from blood and two were from ear swab; 16 (48.5%), 8 (24.2%), 6 (18.1%), 2 (6.1%) and 1 (3.0%) produced MBL, respectively.

Each of MBL positive strains and their MIC results are summarized in Table [2](#Tab2){ref-type="table"}.Table 2**Isolation details, VIM-2 gene results, MICs and sequence type of 33** ***P.aeruginosa*** **MBL positive isolatesIsolateDuration of episode in daysSampleHospitalVIM-2NDM-1IMP-1PMPTcTZTZLCIAKGMIPCTSequence type (ST)**121WoundKAA+\--≥25616≥256≥2562123≥32≥25629BloodKAA+\--126483≥3216≥256≥32≥256336WoundKAA++-8646424≥32≥25612≥32≥256233430WoundKAA+\--4362≥32≥256≥256≥3232233513WoundKAA+\--4361.5≥32≥256≥256≥323268WoundKAA++-64≥256≥256≥256≥32≥256≥256≥32≥25623375WoundKAA+\--24≥256≥256192≥32≥25612≥32≥256810WoundKAA+\--69696240.09442≥32≥256910UrineKAA+\--≥2563≥256≥256≥323212≥32≥256303109BloodKAA+\--241.5≥3222≥3216≥2561175SputumKAA+\--≥256≥256≥256≥256≥32≥25632≥32≥256124WoundKAA+\--624816≥32≥2561.5≥32≥2561981330UrineNCI+\--≥256≥256≥256≥256≥32≥256≥256≥32≥2566291410SputumNCI**-**\--≥25624≥256≥256162≥32≥2561530WoundNCI**-**-+1624164≥3212≥256≥32≥2561646WoundNCI+\--≥256≥256488≥3296≥256≥32≥2562331722SputumNCI+\--612122≥326≥256≥32≥2565071870SputumNCI**-**\--≥2564≥256≥256≥329632≥32≥2561965SputumNCI+\--≥256≥256≥256960.0949632≥32≥25640620120SputumNCI+\--6432122≥3216≥256≥32≥2563032154WoundKAA+\--816244≥3248≥256≥32≥2562332227WoundKAA+\--16≥256≥256≥256≥3212832≥32≥256274237woundKAA+\--256≥256≥56256≥32≥25632≥32≥2568842445UrineKAA+\--812≥25640.0648≥256≥32≥25673825150urineKAA+\--≥256≥256≥256128≥324832≥32≥2562742675WoundKAA+\--≥256≥256≥256≥256≥32≥256≥256≥32≥2566832721UrineKAA+\--16≥256≥256320.064832≥32≥2569902845UrineKAA**-**\--64≥256≥256≥2560.0643232≥32≥25629240UrineKAA+\--241220.12542≥32≥25623330180UrineKAA+\--2481.50.12542≥32≥2562333121WoundKAA+\--81286240.09462≥32≥2563230WoundKAA**-**\--1232280.06462≥32≥2563321Ear swabKAA+\--66≥25683≥3212816≥32233PM = cefepime, PTc = piperacillin/tazobactam, TZL = ceftazidime/clavulanic acid, TZ = ceftazidime, CI = ciprofloxacin, AK = amikacin, GM = gentamicin, IP = imipenem, CT = cefotaxime.

Of the 33 MBL isolates, MBL encoding genes *bla*VIM was identified in 28(85%) isolates, *bla*NDM was identified in 2 (6.1%) isolates and *bla*IMP was identified in only one (3.0%) isolate. In this work MBL *bla*GIM, *bla*SIM, and *bla*SPM allele were not detected. Twenty nine (87.8%) of the MBL-producing isolates were positive for class 1 integron. All the VIM-2 producing isolates had the class 1 integron. All isolates were resistant to imipenem (MIC ≥ 8 μg/ml). Sequencing of intrinsic *bla*VIM confirmed that the nucleotide sequences obtained were identical to genes for VIM-2 for *P.aeruginosa*. Similarly, the nucleotide sequences of class І integron also coincided with the results predicted by the PCR analyses. Eleven distinct STs were identified. Results of STs analyzed are recorded in Table [2](#Tab2){ref-type="table"}. Antibiotic susceptibility result for 33 MBL producing *P.aeruginosa* is given in Table [3](#Tab3){ref-type="table"}.Table 3**Resistance patterns of 33** ***P. aeruginosa*** **MBL positive strainsIsolateType of specimenAntibiotic disk diffusion susceptibility testImipenemAugmentinCefuroximeCefoperzoneCeftazidimeCiprofloxacinMeropenemAmikacinSulperazoneLevofloxacineGentamicinNorfloxacineTazocinCeftriaxonePolymixin B**1WoundRRRRRRRRRRRRRRS2BloodRRRRRRRRIRRRRRS3WoundRRRRRRRRRRRRRRS4WoundRRRRRSRRRRRSRRS5WoundRRRRRRRRRRRRRRS6WoundRRRRRSRRRRRRSRS7WoundRRRRRRRRRRRRRRS8WoundRRRRRSRRRRRRRRS9UrineRRRRRRRRRRRRRRS10BloodRRRRRRRSRRSRRRS11SputumIRRRRIRRRRRRIRS12WoundRRRRRRRRRRRRRRS13UrineRRRRRRRSRRRRRRS14SputumRRRRRIRSRRSRSRS15WoundRRRRRRRSSRRRRRR16WoundRRRRRRRRRRRRRRS17SputumRSRRSRRRRRRRRRS18SputumRRRSSRRRRRRRRSS19SputumRRRRRSRSRRSRRRS20SputumRRRRRRRRRRRRRRS21WoundRRRRRRRRRRRRRRS22WoundRRRRRSRRRSRRRRS23woundRRRRRSRRRSRRRRS24UrineRRRRRRRRRRSRRRS25UrineRRRRRIRRRRRRRRS26WoundRRRRRIRRRRRRRRS27UrineRRRRRRRRRRRRSRS28UrineRRRRRSRRRSRSRRS29UrineRRRRRSRRRRRRRRS30UrineRRRRRRRRRRRRRRS31WoundRRRRRSRRRSRRRRS32WoundRRRRRRRRRRSRSRR33Ear swabRRRRRRRSRRRRRRS

Discussion {#Sec11}
==========

This study clearly demonstrates that carbapenem non-susceptible *P. aeruginosa* is present in Egypt in isolates of different origins mainly isolated from surgical wards with high prevalence of VIM-2 positivity in MBL producing *P.aeruginosa* isolates. The ability of MBL-producing *P. aeruginosa* to reach high level endemicity in certain settings has, indeed, been established, \[[@CR5]\] and in these cases, MBLs can outpace loss of oprD and up-regulated efflux pumps as leading factors causing reduced carbapenem susceptibility; distinct clones even unfolding their potential for causing outbreaks \[[@CR17]\]. Our results revealed that 33 (68.7%) of 48 carbapenem resistant *P.aeruginosa* isolates produced MBL. This study demonstrated an increasing prevalence of MBL. Similarly high prevalence of MBL producing *P.aeruginosa* was detected in the Egyptian study where 82% were MBL producers \[[@CR18]\]. In another Egyptian study 32.3% MBL producing *P.aeruginosa* was observed which is lower than our findings \[[@CR19]\]. In the present study, VIM-2 was the most frequently detectable gene among the different MBL genes investigated; the percent of 85% among carbapenem-resistant MBL producing *P. aeruginosa* was detected. This finding was supported by results of previous studies demonstrating VIM-2 as the most dominant MBL implicated in imipenem resistant *P.aeruginosa* and confers the greatest clinical threat \[[@CR20]\]. Worldwide, VIM-2 is the dominant MBL gene associated with nosocomial outbreaks due to MBL-producing *P. aeruginosa* \[[@CR21]\]. Since MBL-producing isolates can cause serious infections that are difficult to treat, their presence in various hospitals in Egypt is of nationwide concern. The absence of new agents for the treatment of infections caused by these bacteria may lead to treatment failures with increased morbidity and mortality. A class 1 integron carries the integrase gene (intI1), which encodes the site-specific recombinase responsible for cassette insertion. In our study class 1 integron was confirmed in 29 (87.8%) of MBL producing *P.aeruginosa*. This result is consistent with findings from Malaysia in which they suggested that the class 1 integron is the most abundant type of integron present among the clinical isolates of *P.aeruginosa* in Malaysia \[[@CR22]\].

MDR *P.aeruginosa* isolates, resistant to almost all β-lactams, aminoglycosides and quinolones, often ascribed to epidemic clones (ST235 or ST111), have been detected in hospitals worldwide, mainly within ICU \[[@CR23]\]. The increasing prevalence of MDR *P. aeruginosa* isolates is a global health problem, because of the limitation in clinical treatment options. All the VIM-producing isolates in this study belonged to international clones. In this study the results of MLST showed that VIM-2 type MBL carbapenem resistant *P. aeruginosa* specimens isolated from surgical wards of Kasr Al Aini hospital showed similarity in which ST233 which was a part of the internationally dominant clonal cluster CC233 was detected in 7/15 isolates indicating health care acquired transfer of *P.aeruginosa* could occur and should be prevented, an increased risk of cross-transmission and high antimicrobial pressure might have favoured clonal spread. Additionally, patients who have the potential to facilitate dissemination of MDR organisms between hospitals subsequently, might serve as important reservoirs and transmission sources, stressing the importance of hand hygiene compliance, and patient precautions, whereas diversity in sequence types is shown from specimens isolated from NCI where 5 distinct sequence types were observed. This diversity could be due to previous empirical intake of antibiotics or misuse. ST 233 VIM-2 producing *P.aeruginosa* was detected in one isolate imported from Ghana in a study done in Norway and Sweden in which the two international clonal complexes CC111 and CC235 associated with MBL-producing *P. aeruginosa* isolates were dominant \[[@CR24]\]. In previous studies from different Russian states, VIM-2 positive ST 235 was the predominant isolated type that has rapidly spread throughout Russia, Belarus and Kazakhastan via clonal dissemination. The authors were not able to prove the reason for spread of VIM-2 positive ST 235 but explained that inappropriate use of antibiotics and poor adherence to infection control practice could be among the reasons \[[@CR25]\]. Although *P.aeruginosa* clinical isolates are seldom typed and therefore under-reported, ST235 association with VIM-2 seems Europe centered, and has been reported in Belgium, Croatia, Serbia, and, more recently, Greece \[[@CR26]\]. In other parts of Europe ST 111 were the major sequence type detected in MBL producing *P.aeruginosa* and ST 446 was detected but less widespread \[[@CR27]\]. Thus it seems that different clones could be detected from different geographical areas.

Conclusions {#Sec12}
===========

The findings of the present study clearly demonstrate that clones of VIM-2 positive in our hospitals are different from those reported from European studies as none of our isolates revealed ST 235. Prevalence of VIM-2 producers of the same clone was detected from surgical specimens whereas oncology related specimens were showing diverse clones. Similar ST seems to be transmitted due to poor adherence to infection control policies which necessitate efforts for more strict abidance to infection control regulations. Different clones from different specialty hospitals in our study requiring further investigations to explain the relation of diversity of ST types to cause of resistance.
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